NASDAQ:BOLD Boundless Bio (BOLD) Stock Price, News & Analysis $2.79 +0.01 (+0.32%) As of 10:41 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipTrendsBuy This Stock About Boundless Bio Stock (NASDAQ:BOLD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Boundless Bio alerts:Sign Up Key Stats Today's Range$2.78▼$2.8050-Day Range$1.38▼$2.8952-Week Range$0.96▼$2.97Volume1,506 shsAverage Volume633,682 shsMarket Capitalization$63.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. Read More Boundless Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreBOLD MarketRank™: Boundless Bio scored higher than 36% of companies evaluated by MarketBeat, and ranked 719th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.9 / 5Analyst RatingSell Consensus RatingBoundless Bio has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 2 sell ratings.Amount of Analyst CoverageBoundless Bio has only been the subject of 2 research reports in the past 90 days.Read more about Boundless Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Boundless Bio is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Boundless Bio is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBoundless Bio has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.30% of the float of Boundless Bio has been sold short.Short Interest Ratio / Days to CoverBoundless Bio has a short interest ratio ("days to cover") of 1.52, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Boundless Bio has recently decreased by 6.91%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBoundless Bio does not currently pay a dividend.Dividend GrowthBoundless Bio does not have a long track record of dividend growth. News and Social Media2.8 / 5News SentimentN/A News SentimentBoundless Bio has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Boundless Bio this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for BOLD on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $565,005.00 in company stock, which represents 0.8934% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Boundless Bio insiders have bought 709.09% more of their company's stock than they have sold. Specifically, they have bought $644,685.00 in company stock and sold $79,680.00 in company stock.Percentage Held by Insiders23.10% of the stock of Boundless Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsBoundless Bio has minimal institutional ownership at this time.Read more about Boundless Bio's insider trading history. Receive BOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Boundless Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BOLD Stock News HeadlinesHalper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their ShareholdersJuly 2, 2026 | globenewswire.comBoundless Bio to merge with Serapha Bio in reverse merger; shares surgeJune 23, 2026 | msn.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.August 14 at 1:00 AM | Porter & Company (Ad)BOLD Stock Is Up 90% — Here's What's Behind The Biggest Rally In Company HistoryJune 23, 2026 | finance.yahoo.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)June 23, 2026 | prnewswire.comBoundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private PlacementJune 23, 2026 | globenewswire.comBoundless Bio Reports First Quarter 2026 Financial Results and Business HighlightsMay 8, 2026 | globenewswire.comBoundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual MeetingApril 17, 2026 | globenewswire.comSee More Headlines BOLD Stock Analysis - Frequently Asked Questions How have BOLD shares performed this year? Boundless Bio's stock was trading at $1.18 at the beginning of the year. Since then, BOLD stock has increased by 135.6% and is now trading at $2.78. How were Boundless Bio's earnings last quarter? Boundless Bio, Inc. (NASDAQ:BOLD) posted its quarterly earnings data on Friday, August, 7th. The biotechnology company reported ($1.06) EPS for the quarter. When did Boundless Bio IPO? Boundless Bio (BOLD) raised $100 million in an initial public offering on Thursday, March 28th 2024. The company issued 6,250,000 shares at a price of $15.00-$17.00 per share. Who are Boundless Bio's major shareholders? Boundless Bio's top institutional shareholders include BlackRock Inc. (0.39%) and GSA Capital Partners LLP (0.32%). Insiders that own company stock include Ra Capital Management, LP and Venture Fund Ix LP Arch. View institutional ownership trends. How do I buy shares of Boundless Bio? Shares of BOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Boundless Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Boundless Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alphabet (GOOG) and Visa (V). Company Calendar Last Earnings8/07/2026Today8/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 BOLD's financial health is in the Green zone, according to TradeSmith. BOLD has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BOLD CIK0001782303 Webwww.boundlessbio.com Phone(858) 766-9912FaxN/AEmployees64Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$58.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-65.05% Return on Assets-41.14% Debt Debt-to-Equity Ratio0.52 Current Ratio9.87 Quick Ratio9.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.41 per share Price / Book0.63Miscellaneous Outstanding Shares22,750,000Free Float17,493,000Market Cap$63.54 million OptionableNo Data Beta-0.08 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:BOLD) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersAmerican retirees will miss THIS. Big Banks just moved in.Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...Cedar Gold Group | SponsoredThe options guide that actually starts at the beginningMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | SponsoredAfter KDA, PRE, and OCEAN—this is the one17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredHow the JPMorgan $8,000 Gold Call Exposed the Biggest Mistake in Most Retirement AccountsJPMorgan has raised its 2026 gold forecast to $6,300, with a credible path to $8,000, and now calls gold a cor...Golden Crest Metals | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Boundless Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Boundless Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BOLD Stock Alerts